DISEASE FOCUS / MARKET OPPORTUNITY
IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders: UC and CD.
IBD affects millions of individuals worldwide. In the United States, it is estimated that approximately 2.4 million individuals are currently diagnosed with IBD.
A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. Treatment plans are often tailored to the individual’s disease severity, location, and response to therapy. In some cases, surgical interventions such as bowel resection or ostomy formation may be necessary.There remain substantial unmet needs in IBD management, including: